SARS-CoV-2 Variant Testing

Abstract The robust protection conferred by emerging EUA approved SARS-CoV-2 vaccines represents a critical milestone in COVID-19 vaccine development. However, the emergence of variants has inspired renewed concern related to the protective efficacy of currently approved vaccines, which lose neutralizing potency against some variants. However, emerging data suggest that antibody functions, beyond neutralization, that emerge early after vaccination and that persist even with a loss of neutralization, may contribute to protection from disease. Thus, here we aim to profile the evolution of the breadth of the VOC-specific Fc-effector functions of vaccine induced antibodies across vaccine platforms. Specifically, we aim to profile the subclass, isotypes, Fc-receptor binding, complement depositing function, cellular cytotoxicity, opsinophagocytic activity, degranulation, and mucus trapping days after vaccination compared to convalescent individuals. These data will be compared to breakthrough infection cases from Novavax (& Medicago) and J&J.